我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 Cipher Pharmaceuticals, Inc.
相关临床试验
11
0 进行中
药物批准
4
批准总数
监管机构
1
监管机构数
成立时间
2002
已完成
100.0%
FDA
Food and Drug Administration
- Moberg Pharma reports that a subset of patients in their North American Phase 3 study of MOB-015 achieved clinical cure for nail fungus at a rate lower than anticipated. - Cipher Pharmaceuticals, which holds Canadian marketing rights to MOB-015, acknowledges the update from Moberg Pharma regarding the clinical trial results. - Cipher Pharmaceuticals emphasizes that the outcome of the MOB-015 trial does not currently impact the company's sales and earnings profile. - Cipher Pharmaceuticals remains focused on the integration of the Natroba™ business and other potential growth opportunities.
